Dirk Schadendorf

Researcher Next ID · RN-001728

Researcher · Biochemistry, Genetics and Molecular Biology

Heidelberg, Germany

Not currently recruitingFunding unknown

Research interests

Biochemistry, Genetics and Molecular Biology

Medicine

Immunology and Microbiology

Melanoma and MAPK Pathways

Cutaneous Melanoma Detection and Management

Cancer Immunotherapy and Biomarkers

Immunotherapy and Immune Responses

CAR-T cell therapy research

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1709684
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
New England Journal of Medicine · 2015 · https://doi.org/10.1056/nejmoa1504030
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1412082
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
New England Journal of Medicine · 2011 · https://doi.org/10.1056/nejmoa1103782
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
New England Journal of Medicine · 2010 · https://doi.org/10.1056/nejmoa1003466

No projects listed.